REPEAT - Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alex Makriyannis, PhD, Joins ICC Funded Biosynthesis Cannabinoid Company; to Champion Cannabinoid Pharmaceutical Research and THC/CBD Edibles Application Mandates

Stock Information for ICC International Cannabis Corp (New)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ICC International Cannabis Corp (New)

International Cannabis Applies for Voluntary Delisting from Canadian Securities Exchange
International Cannabis Provides Transaction Guidance
Pfizer, Bristol-Myers Squibb, and Biogen Advisor, Dr. Alex Makriyannis, PhD, Joins ICC Funded Biosynthesis Cannabinoid Company; to Champion Cannabinoid Pharmaceutical Research and THC/CBD Edibles Application Mandates
REPEAT - International Cannabis to Supply New Zealand's NUBU Pharmaceuticals With Portfolio of Full-Spectrum Pharmaceutical THC/CBD Products
International Cannabis to Supply New Zealand's NUBU Pharmaceuticals With Portfolio of Full-Spectrum Pharmaceutical THC/CBD Products
Horizons ETFs Rebalances Marijuana-Focused ETFs
REPEAT - AgraFlora Organics Reviews Vertically Integrated Asset Portfolio
REPEAT - International Cannabis Completes Technical Feasibility Study for Danish GACP/EU-GMP Certified Greenfield Cultivation and Processing Facility; Forecasted 2021 Production of Circa 20,000,000 Grams of Dried Flower

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.